-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Corbus Pharmaceuticals Holdings, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2020 to 2023.
- Corbus Pharmaceuticals Holdings, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2024 was -$13.2M, a 31.4% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2024 was -$38.5M, a 18.6% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$44.5M, a 4.88% decline from 2022.
- Corbus Pharmaceuticals Holdings, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$42.4M, a 7.2% increase from 2021.
- Corbus Pharmaceuticals Holdings, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$45.7M, a 58.9% increase from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)